TargetBeta
PPARA
peroxisome proliferator activated receptor alpha · also hPPAR, NR1C1, PPAR · Peroxisome proliferator activated receptors
7 programs in company-led studies act on PPARA, from 7 companies: 5 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| saroglitazarrule | Zydus Lifesciences | phase 4 | 196 running | PPARG | ChEMBL |
| pemafibraterule | Kowa | phase 4 | 171 running | – | ChEMBL |
| elifibranorrule | Genfit | phase 3 | 245 running | PPARD | NCIt |
| seladelparrule | Gilead Sciences | phase 3 | 143 running | PPARD | NCIt |
| Gemfibrozilrule | Polaryx Therapeutics | phase 3 | 81 running | – | ChEMBL |
| lanifibranor | Inventiva Pharma | phase 3 | 61 running | PPARD, PPARG | the company's pipeline |
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 90 running | PPARD, PPARG | ChEMBL |
Conditions their studies are in
- Non-alcoholic Fatty Liver Disease, 5 programs
- Liver Cirrhosis, Biliary, 4 programs
- Diabetes Mellitus, Type 2, 3 programs
- Renal Insufficiency, 3 programs
- Cholangitis, Sclerosing, 2 programs
- Dyslipidemias, 2 programs
- Hyperlipidemias, 2 programs
- Anemia, 1 program
- Fibrosis, 1 program
- Homozygous Familial Hypercholesterolemia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 17, 2026elifibranor · Genfit · phase 3 · NCT06730061
- Dec 31, 2026saroglitazar · Zydus Lifesciences · phase 4 · NCT05045482
- Jul 31, 2027pemafibrate · Kowa · phase 4 · NCT07634484
- Nov 2028seladelpar · Gilead Sciences · phase 3 · NCT03301506
- Dec 31, 2028Gemfibrozil · Polaryx Therapeutics · phase 3 · NCT07740512
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.